Our observation that HDAC class I inhibitors block aberrant transcript elongation caused by AF4-MLL suggests that HDAC class I inhibitors might be of considerable therapeutic interest for t(4,11)-leukemias. This evidence concerns the gene HDAC9 and leukemia.